Quinazoline Compounds Modulate Ras Signaling via SOS Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to inhibiting Ras-driven tumors have limitations, particularly in targeting the Ras signaling pathway effectively, as they often disrupt posttranslational modifications or inhibit Ras effectors, without adequately addressing the core issue of aberrant Ras activity in cancer cells.
Innovation Solution
Development of compounds that bind to a hydrophobic pocket on the SOS protein within the Ras:SOS:Ras complex, enhancing SOS-mediated nucleotide exchange and altering Ras activity, thereby modulating Ras signaling pathways in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds bind to the hydrophobic pocket on SOS protein to enhance nucleotide exchange, then Ras-GTP levels increase and cancer cell death is induced, but the complexity of targeting the Ras signaling pathway increases due to the trimeric Ras:SOS:Ras complex structure
Solution Approach 1:
The patent uses SOS protein as an intermediary target rather than directly targeting Ras. By binding to the hydrophobic pocket on SOS within the trimeric Ras:SOS:Ras complex, the compounds indirectly modulate Ras activity and enhance nucleotide exchange, thereby inducing cancer cell death while avoiding the complexity of directly targeting the trimeric complex structure
Solution Approach 2:
The compounds specifically bind to a localized hydrophobic pocket on the SOS protein within the trimeric complex, rather than attempting to interact with the entire complex. This localized binding approach allows selective modulation of SOS-mediated nucleotide exchange while maintaining specificity and avoiding off-target effects
2Reliability
If traditional approaches disrupt posttranslational modifications or inhibit Ras effectors, then Ras signaling is blocked, but the effectiveness is limited due to inadequate addressing of aberrant Ras activity
Solution Approach 1:
Instead of inhibiting Ras activity or blocking its effectors as in traditional approaches, the patent inverts the strategy by enhancing SOS-mediated nucleotide exchange to increase Ras-GTP levels. This paradoxical approach of activating Ras through SOS modulation ultimately leads to cancer cell death by perturbing downstream MAPK and PI3K signaling pathways
Solution Approach 2:
The patent extracts and targets a specific functional element (the hydrophobic pocket on SOS protein) within the larger Ras signaling system. By focusing on this specific pocket that mediates nucleotide exchange activity, the compounds achieve selective modulation of Ras signaling without needing to disrupt multiple posttranslational modifications or target multiple effectors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase Ras-GTP levels, perturb MAPK and PI3K signaling pathways, leading to cancer cell death and providing a novel approach for treating Ras-driven tumors.
Implementation Method 1
compounds that bind to a hydrophobic pocket on the SOS protein, as part of the Ras:SOS:Ras complex
Data Source
AI summary
The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.